✦ LIBER ✦

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors

✍ Scribed by Wells A. Messersmith; Antonio Jimeno; David Ettinger; Dan Laheru; Julie Brahmer; Dina Lansey; Yasmin Khan; Ross C. Donehower; Yusri Elsayed; Peter Zannikos; Manuel Hidalgo

Publisher: Springer
Year: 2008
Tongue: English
Weight: 316 KB
Volume: 63
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-008-0733-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I clinical trial of bortezomib in

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi

A phase I trial of gemcitabine in combin

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

✍ William Schelman; Sherry Morgan-Meadows; Howard Bailey; Kyle Holen; James P. Tho 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 325 KB

A phase I trial of topotecan and gemcita

A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors

✍ Weijing Sun; James P. Stevenson; Maryann Gallagher; Bruce Giantonio; Kenneth Alg 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

Phase I trial of weekly docetaxel and ge

Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies

✍ Tarek Mekhail; Thomas E. Hutson; Paul Elson; G. Thomas Budd; Gordon Srkalovic; T 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

## Abstract ## BACKGROUND A Phase I study using weekly docetaxel and gemcitabine was conducted to investigate toxicity; to determine the maximum tolerated dose (MTD) of each agent; and, in a preliminary fashion, to determine the antitumor activity of the combination. ## METHODS Docetaxel and gem

A phase I trial of perillyl alcohol in p

A phase I trial of perillyl alcohol in patients with advanced solid tumors

✍ Christopher G. Azzoli; Vincent A. Miller; Kenneth K. Ng; Lee M. Krug; David R. S 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 232 KB

Phase I clinical trial of weekly combine

Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors

✍ Jacob Lokich 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

A Phase I and feasibility study of combined docetaxel (D) plus paclitaxel (P) was undertaken to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) for each analogue delivered concomitantly on a weekly schedule. ## METHODS. Patients were accrued in 3-6 patient cohorts to P